CAD & Atherosclerosis
From the Journals
SPRINT’s intensive therapy benefit fades once BP creeps back up
Despite an all-cause mortality benefit from intensive therapy in SPRINT, benefit was lost after the trial.
Conference Coverage
Tirzepatide’s benefits expand: Lean mass up, serum lipids down
New results from the SURMOUNT-1 trial of tirzepatide in people with obesity show further positive effects.
From the Journals
Bariatric surgery prompts visceral fat reduction, cardiac changes
Weight loss after bariatric surgery was tied to favorable cardiac effects associated with reduction in visceral fat.
From the Journals
Retinal imaging can predict cardiovascular mortality
The system “paves the way for a highly effective, noninvasive screening test for people at medium to high risk of circulatory disease that doesn’t...
From the Journals
Food insecurity a growing problem for many with CVD
The number of Americans with cardiovascular disease who have limited or uncertain access to food has more than doubled over the last 20 years.
From the Journals
SMART-CHOICE 3-year results support dropping aspirin after PCI
The antiplatelet strategy after PCI is currently shifting to reduce the duration of DAPT.
From the Journals
Aspirin primary prevention benefit in those with raised Lp(a)?
A new analysis of the ASPREE primary prevention trial of aspirin has shown a net clinical benefit in those with genotypes associated with raised...
From the Journals
Coffee linked to reduced cardiovascular disease and mortality risk
Two to three cups per day of ground, instant, or decaf coffee is linked to lower risk of mortality and cardiovascular disease, and can be...
Conference Coverage
Cre8 EVO stent loses sweet spot in diabetes at 2 years: SUGAR
Outcomes once deemed “almost too good to be true” disappeared with longer follow-up in an all-comer population of patients with diabetes...
From the Journals
Uncontrolled BP linked to one-third of ED visits for CVD
In a sample of more than 20 million emergency department visits, about one-third of CVD-related visits were related to poorly controlled...
Conference Coverage
Add PCSK9 inhibitor to high-intensity statin at primary PCI, proposes sham-controlled EPIC-STEMI
The powerful LDL cholesterol–lowering agents aren’t being used to their fullest potential, but giving them early to STEMI patients along with high...